Company
Cyrano
The first pharmaceutical therapy for taste and smell loss.
Also known as Cyrano Therapeutics, Cyrano Therapeutics, Inc.
- Status
- Operatingas of 2026-09-17
- Legal name
- Cyrano Therapeutics, Inc.
- cyranotherapeutics.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
At Cyrano Therapeutics, we’re dedicated to developing therapies for people dealing with long-term loss of smell and taste. Prior to the COVID-19 pandemic, this condition affected over 15 million people in the U.S., with about 4 million cases resulting from flu viruses. Since COVID-19, however, the prevalence has increased over tenfold, with thousands of new cases emerging daily. This surge highlights the urgent need for effective treatments, and we’re committed to advancing solutions that restore these essential senses and enhance quality of life for those impacted.
Funding snapshot
- Total raised
- $4.1MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $4.1M2020-11-04
Funding rounds
- Round, 2020
- $4.1M2020-11-04, SEC form D sold, 11 investors
Products
- Other
- CYR-064
Loading relationship preview